Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGH-478 for Moderate to Severe Pain in Osteoarthritis of the Knee
2011-000931-10Phase 2Completed
- Sponsor
- Gedeon Richter Plc
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RGH-478 in knee osteoarthritis (OA) (3 arms), sponsored by Gedeon Richter Plc. Primary endpoint: Primary efficacy: change in WOMAC pain VAS. Started May 2011; status: completed.
02
Drugs
RGH-478
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2011-000931-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000931-10.